Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial

被引：16

作者：

Hegde, Meenakshi ^{[1
,2
,3
,4
]}

Navai, Shoba ^{[1
,2
,3
,4
]}

DeRenzo, Christopher ^{[1
,2
,3
,16
]}

Joseph, Sujith K. ^{[1
,2
,3
,4
]}

Sanber, Khaled ^{[1
,2
,5
]}

Wu, Mengfen ^{[4
]}

Gad, Ahmed Z. ^{[1
,2
,3
,6
]}

Janeway, Katherine A. ^{[7
]}

Campbell, Matthew ^{[1
,2
,3
]}

Mullikin, Dolores ^{[1
,2
,3
]}

Nawas, Zeid ^{[1
,2
,3
]}

Robertson, Catherine ^{[2
]}

Mathew, Pretty R. ^{[1
,2
,3
]}

Zhang, Huimin ^{[2
]}

Mehta, Birju ^{[2
]}

Bhat, Raksha R. ^{[1
,2
,3
]}

Major, Angela ^{[8
]}

Shree, Ankita ^{[1
,2
,3
]}

Gerken, Claudia ^{[1
,2
,3
]}

Kalra, Mamta ^{[1
,2
,3
]}

Chakraborty, Rikhia ^{[1
,3
,4
]}

Thakkar, Sachin G. ^{[2
]}

Dakhova, Olga ^{[2
]}

Salsman, Vita S. ^{[1
,2
,3
]}

Grilley, Bambi ^{[1
,2
,3
,4
]}

Lapteva, Natalia ^{[2
,8
]}

Gee, Adrian ^{[1
,2
,3
]}

Dotti, Gianpietro ^{[9
]}

Bao, Riyue ^{[10
,11
]}

Salem, Ahmed Hamed ^{[12
]}

Wang, Tao ^{[4
]}

Brenner, Malcolm K. ^{[1
,2
,3
,4
,5
]}

Heslop, Helen E. ^{[1
,2
,3
,4
,5
]}

Wels, Winfried S. ^{[13
,14
,15
]}

Hicks, M. John ^{[1
,8
]}

Gottschalk, Stephen ^{[1
,2
,3
,4
,16
]}

Ahmed, Nabil ^{[1
,2
,3
,4
,8
]}

机构：

[1] Texas Childrens Hosp, Baylor Coll Med, Texas Childrens Canc & Hematol Ctr, Houston, TX 77030 USA

[2] Houston Methodist Hosp, Texas Childrens Hosp, Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA

[3] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA

[4] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA

[5] Baylor Coll Med, Dept Med, Houston, TX USA

[6] Baylor Coll Med, Interdept Program Translat Biol & Mol Med, Houston, TX USA

[7] Boston Childrens Hosp, Dana Farber Canc Inst, Harvard Med Sch, Dept Pediat, Boston, MA USA

[8] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA

[9] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA

[10] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA

[11] UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[12] Ain Shams Univ, Dept Clin Pharm, Fac Pharm, Cairo, Egypt

[13] Inst Tumor Biol & Expt Therapy, Georg Speyer Haus, Frankfurt, Germany

[14] German Canc Consortium DKTK, Partner Site Frankfurt Mainz, Frankfurt, Germany

[15] Goethe Univ, Frankfurt Canc Inst, Frankfurt, Germany

[16] St Jude Childrens Res Hosp, Dept Bone Marrow Transplantat & Cellular Therapy, Memphis, TN USA

来源：

NATURE CANCER | 2024年 / 5卷 / 06期

关键词：

YOUNG-ADULT PATIENTS; MONOCLONAL-ANTIBODY; ANTITUMOR-ACTIVITY; ONCOLOGY-GROUP; B-CELL; OSTEOSARCOMA; CHEMOTHERAPY; TRASTUZUMAB; EFFICACY; IMMUNOTHERAPY;

D O I：

10.1038/s43018-024-00749-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In this prospective, interventional phase 1 study for individuals with advanced sarcoma, we infused autologous HER2-specific chimeric antigen receptor T cells (HER2 CAR T cells) after lymphodepletion with fludarabine (Flu) +/- cyclophosphamide (Cy): 1 x 108 T cells per m2 after Flu (cohort A) or Flu/Cy (cohort B) and 1 x 108 CAR+ T cells per m2 after Flu/Cy (cohort C). The primary outcome was assessment of safety of one dose of HER2 CAR T cells after lymphodepletion. Determination of antitumor responses was the secondary outcome. Thirteen individuals were treated in 14 enrollments, and seven received multiple infusions. HER2 CAR T cells expanded after 19 of 21 infusions. Nine of 12 individuals in cohorts A and B developed grade 1-2 cytokine release syndrome. Two individuals in cohort C experienced dose-limiting toxicity with grade 3-4 cytokine release syndrome. Antitumor activity was observed with clinical benefit in 50% of individuals treated. The tumor samples analyzed showed spatial heterogeneity of immune cells and clustering by sarcoma type and by treatment response. Our results affirm HER2 as a CAR T cell target and demonstrate the safety of this therapeutic approach in sarcoma. ClinicalTrials.gov registration: NCT00902044. In this phase 1 trial, Hegde et al. treat 13 individuals with advanced sarcoma with lymphodepletion followed by HER2-specific CAR T cells, which were found to be safe and showed antitumor activity.

引用

页码：880 / 894

页数：31

共 50 条

[31] Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies
Szoor, Arpad
Toth, Gabor
Zsebik, Barbara
Szabo, Viktoria
Eshhar, Zelig
Abken, Hinrich
Vereb, Gyorgy
CANCER LETTERS, 2020, 484 : 1 - 8
[32] HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer
Xu, Jie
Meng, Qingtao
Sun, Hao
Zhang, Xinwei
Yun, Jun
Li, Bin
Wu, Shenshen
Li, Xiaobo
Yang, Hongbao
Zhu, Haitao
Aschner, Michael
Relucenti, Michela
Familiari, Giuseppe
Chen, Rui
CELL DEATH & DISEASE, 2021, 12 (12)
[33] Genetically engineered T cells expressing a HER2-specific chimeric receptor mediate antigen-specific tumor regression
Li, S.
Yang, J.
Urban, F. A.
MacGregor, J. N.
Hughes, D. P. M.
Chang, A. E.
Mcdonagh, K. T.
Li, Q.
CANCER GENE THERAPY, 2008, 15 (06) : 382 - 392
[34] Genetically engineered T cells expressing a HER2-specific chimeric receptor mediate antigen-specific tumor regression
S Li
J Yang
F A Urban
J N MacGregor
D P M Hughes
A E Chang
K T Mcdonagh
Q Li
Cancer Gene Therapy, 2008, 15 : 382 - 392
[35] HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer
Jie Xu
Qingtao Meng
Hao Sun
Xinwei Zhang
Jun Yun
Bin Li
Shenshen Wu
Xiaobo Li
Hongbao Yang
Haitao Zhu
Michael Aschner
Michela Relucenti
Giuseppe Familiari
Rui Chen
Cell Death & Disease, 12
[36] Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma
Mason, Nicola J.
Gnanandarajah, Josephine S.
Engiles, Julie B.
Gray, Falon
Laughlin, Danielle
Gaurnier-Hausser, Anita
Wallecha, Anu
Huebner, Margie
Paterson, Yvonne
CLINICAL CANCER RESEARCH, 2016, 22 (17) : 4380 - 4390
[37] HER2-specific Affibody Molecule [99mTc]Tc-ZHER2:41071: phase I clinical trial
Tolmachev, Vladimir
Bragina, Olga
Chernov, Vladimir
Larkina, Maria
Rybina, Anastasiya
Zelchan, Roman
Oroujeni, Maryam
Loftenius, Annika
Orlova, Anna
Sorensen, Jens
Frejd, Fredrik
NUCLEAR MEDICINE AND BIOLOGY, 2023, 126 : S197 - S198
[38] Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
Qi, Changsong
Gong, Jifang
Li, Jian
Liu, Dan
Qin, Yanru
Ge, Sai
Zhang, Miao
Peng, Zhi
Zhou, Jun
Cao, Yanshuo
Zhang, Xiaotian
Lu, Zhihao
Lu, Ming
Yuan, Jiajia
Wang, Zhenghang
Wang, Yakun
Peng, Xiaohui
Gao, Huiping
Liu, Zhen
Wang, Huamao
Yuan, Daijing
Xiao, Jun
Ma, Hong
Wang, Wei
Li, Zonghai
Shen, Lin
NATURE MEDICINE, 2022, 28 (06) : 1189 - +
[39] Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
Qi, Changsong
Liu, Chang
Gong, Jifang
Liu, Dan
Wang, Xicheng
Zhang, Panpan
Qin, Yanru
Ge, Sai
Zhang, Miao
Peng, Zhi
Zhou, Jun
Lu, Zhihao
Lu, Ming
Cao, Yanshuo
Yuan, Jiajia
Wang, Yakun
Wang, Zhenghang
Xue, Ran
Peng, Xiaohui
Wang, Yumeng
Yuan, Daijing
Li, Jian
Zhang, Xiaotian
Shen, Lin
NATURE MEDICINE, 2024, 30 (08) : 2224 - 2234
[40] Universal CAR T cells targeted with HER2-specific soluble linker penetrate spheroids and large tumour xenografts that are inherently resistant to trastuzumab-mediated ADCC
Nagy, L.
Mezosi-Csaplar, M.
Rebenku, I.
Vereb, G.
Szoor, A.
HUMAN GENE THERAPY, 2024, 35 (3-4) : A211 - A211

← 1 2 3 4 5 →